Patent Fight on Galvus Soar: Novartis Now Sues Biocon
Swiss giant Novartis has dragged Biocon to Delhi High Court for allegedly infringing patent rights of its diabetes drug “Galvus” and now Biocon cannot manufacture, sell or export vildagliptin until the next hearing. The multinational is seeking an injunction...